Arcturus focuses on the application of messenger RNA therapeutics for the treatment of diseases. . There are currently five key issues in the field of messenger RNA therapeutics, including 1)limited ‘composition of matter’ IP around the API mRNA; 2) insufficient delivery of mRNA, especially in primates; 3) insufficient stability of nanoparticles that contain mRNA; 4) short half-life of mRNA after it is delivered into the target cell; and 5) decreased potency after repeat dosing is observed.
Arcturus scientists have addressed all five of the issues above with two proprietary technologies that solve the major hurdles in RNA medicine development. Their Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR™) delivery platform and their unlocked nucleomonomer agent (UNA) Oligomer technology can be used together or separately with the potential to create the next-generation of safer and more, effective RNA medicines.
LUNAR enables systemic delivery of all types of RNA therapeutics to target specific tissues. UNA oligomers are more stable, more potent and less toxic than standard oligomers.
We are very passionate about finding transformative RNA medicines for patients suffering from serious rare genetic diseases.
“JLABS allowed Arcturus to secure the infrastructure and equipment (i.e. quality space, office, materials, lab benches, refrigeration units, freezer, specialized equipment) to quickly generate proof of concept data,” said Joseph E. Payne, President and CEO of Arcturus Therapeutics. “Pad and I also appreciated the community of entrepreneurs and other mentors that JLABS offered – a great environment to progress challenging science. In less than 2 years we were able to graduate and expand operations.”
Meet the Team:
Joseph E. Payne (President & CEO)
Padmanabh Chivukula, CSO & COO